Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice

Journal of Cellular Physiology

Volumn 204, Issue 1, 2005, Pages 73-82

  Gu, Jian Ming ^a   Johns, Anthony ^a   Morser, John ^a   Dole, William P ^a   Greaves, David R ^b   Deng, Gary G ^a,c  

^a BAYER AG   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA M ANTIBODY; ANGIOTENSIN; ANTIBODY; APOLIPOPROTEIN E; CD11B ANTIGEN; CD68 ANTIGEN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; MATRIX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

ANIMAL CELL; AORTA WALL; ARTICLE; BLOOD VESSEL WALL; CELL ADHESION; CELL INFILTRATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MACROPHAGE; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD11B; AORTA; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CELL LINE; CELL MOVEMENT; HUMANS; KIDNEY; MACROPHAGE-1 ANTIGEN; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TRANSFECTION; URINARY PLASMINOGEN ACTIVATOR; VASCULITIS;

MURINAE;

EID: 20144379710     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20262     Document Type: Article

References (49)

1. Aguirre Ghiso JA, Kovalski K, Ossowski L. 1999. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147(1):89-104.
2. Aguirre Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. 2001. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12(4):863-879.
3. Balabanov R, Lisak D, Beaumont T, Lisak RP, Dore-Duffy P. 2001. Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: Effect of glatiramer acetate (copolymer 1). Clin Diagn Lab Immunol 8(6):1196-1203.
4. Blasi F, Carmeliet P. 2002. uPAR: A versatile signaling orchestrator. Nat Rev Mol Cell Biol 3(12):932-943.
5. Bohuslav J, Horejsi V, Hansmann C, Stockl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H. 1995. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 181(4):1381-1390.
6. -/-) fed a fat or a chow diet. Atherioscler Thromb Vasc Biol 20(12):2630-2635.
7. Chen BC, Lin WW. 2000. Pyridinoceptor potentiation of macrophage PGE2 release involved in the induction of nitric oxide synthase. Br J Pharmacol 130(4):777-786.
8. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. 2000. P-selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 191(1): 189-194.
9. Curci JA, Liao S, Huffman MD, Shapiro SD, Thompson RW. 1998. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest 102(11):1900-1910.
10. Daugherty A, Manning MW, Cassis LA. 2000. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105(11):1605-1612.
11. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. 1996. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134(6):1563-1571.
12. Deng G, Curriden SA, Hu G, Czekay RP, Loskutoff DJ. 2001. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 189(1):23-33.
13. Estreicher A, Wohlwend A, Belin D, Schleuning W-D, Vassalli J-D. 1989. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 264(2):1180-1189.
14. Gough PJ, Gordon S, Greaves DR. 2001. The use of human CD68 transcriptional regulatory sequences to direct high-level expression of class A scavenger receptor in macrophages in vitro and in vivo. Immunology 103(3):351-361.
15. Greaves DR, Quinn CM, Seldin MF, Gordon S. 1998. Functional comparison of the murine macrosialin and human CD68 promoters in macrophage and nonmacrophage cell lines. Genomics 54(1):165-168.
16. Gyetko MR, Todd RF 3rd, Wilkinson CC, Sitrin RG. 1994. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93(4):1380-1387.
17. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ. 2000. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 165(3): 1513-1519.
18. Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD, Cybulsky MI. 1999. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 85(2):199-207.
19. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. 1986. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6(2):131-138.
20. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. 1996. The urokinase receptor is a major vitronectin binding protein on endothelial cells. Exp Cell Res 224(2):344-353.
21. Kitagawa K, Matsumoto M, Sasaki T, Hashimoto H, Kuwabara K, Ohtsuki T, Hori M. 2002. Involvement of ICAM-1 in the progression of atherosclerosis in ApoE-knockout mice. Atherosclerosis 160(2):305-310.
22. Knowles JW, Maeda N. 2000. Genetic modifiers of atherosclerosis in mice. Arterioscler Thromb Vasc Biol 20(11):2336-2345.
23. Kranzhofer R, Browatzki M, Schmidt J, Kubler W. 1999. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappa B in human monocytes. Biochem Biophys Res Comm 257(3):826-828.
24. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. 1998. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med 188(6):1029-1037.
25. May AE, Schmidt R, Kanse SM, Chavakis T, Stephens RW, Schoming A, Preissner KT, Neumann FJ. 2002. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 100(10):3611-3617.
26. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. 1998. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 18(5):842-851.
27. Nguyen DH, Hussaini IM, Gonias SL. 1998. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 273(14):8502-8507.
28. Nguyen DH, Catling AD, Webb DJ, Sankovic M, Walker LA, Somlyo AV, Weber MJ, Gonias SL. 1999. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol 146(1):149-164.
29. Ossowski L, Aguirre-Ghiso JA. 2000. Urokinase receptor and integrin partnership: Coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12(5):613-620.
30. Petty HR, Todd RF 3rd. 1996. Integrins as promiscuous signal transduction devices. Immunol Today 17(5):209-212.
31. Poston RN, Haskard DO, Coucher JH, Gall NP, Johnson-Tidey RR. 1992. Expression of intercellular adhesion molecule-1 in atherotic plaques. Am J Pathol 140(3):665-673.
32. Price DT, Loscalzo J. 1999. Cellular adhesion molecules and atherogenesis. Am J Med 107(1):85-97.
33. Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. 1995. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 15(9):1432-1443.
34. Ross R. 1999. Atherosclerosis - An inflammatory disease. New Engl J Med 340(2): 115-126.
35. Salame MY, Samani NJ, Masood I, deBono DP. 2000. Expression of the plasminogen activator system in the human vascular wall. Atherosclerosis 152(1): 19-28.
36. Sanchez-Madrid F, Simon P, Thompson S, Springer TA. 1983. Mapping of antigenic and functional epitopes on the alpha- and beta-subunits of two related mouse glycoproteins involved in cell interactions, LFA-1 and Mac-1. J Exp Med 158:586-602.
37. Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Ronne E, Kobzik L, Chapman HA. 1996. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 88(8):3185-3194.
38. Simon DI, Wei Y, Zhang L, Rao NK, Xu H, Chen Z, Liu Q, Rosenberg S, Chapman HA. 2000. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem 275(14):10228-10234.
39. Sitrin RG, Todd RF 3rd, Albrecht E, Gyetko MR. 1996. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 97(8):1942-1951.
40. Springer TA. 1990. Adhesion receptors of the immune system. Nature 346(6283): 425-434.
41. Tham DM, Martin-McNulty B, Wang Y-X, Wilson DW, Vergona R, Sullivan ME, Dole WP, Rutledge JC. 2002. Angiotensin II is associated with activation of NF-kB-mediated genes and down-regulation of PPARs. Physiol Genomics 11(1):21-30.
42. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG, Medford RM. 1999. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the rennin-angiotensin system and atherosclerosis. Circulation 100(11):1223-1229.
43. Van der Pluijm G, Sijmons B, Vloedgraven H, van der Bent C, Drijfhout JW, Verheijen J, Ouax P, Karperien M, Papapoulos S, Lowik C. 2001. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 159(3):971-982.
44. Wang YX, Martin-McNulty B, Freay AD, Sukovich DA, Halks-Miller M, Li WW, Vergona R, Sullivan ME, Morser J, Dole WP, Deng GG. 2001. Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice. Am J Pathol 159(4):1455-1464.
45. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg J, Chapman HA. 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269(51):32380-32388.
46. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. 1996. Regulation of integrin function by the urokinase receptor. Science 273(5281):1551-1555.
47. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. 1999. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 144(6):1285-1294.
48. Wilcox-Adelman SA, Wilkins-Port CE, McKeown-Longo PJ. 2000. Localization of urokinase type plasminogen activator to focal adhesions requires ligation of vitronectin integrin receptors. Cell Adhes Commun 7(6):477-490.
49. Yebra M, Goretzki L, Pfeifer M, Mueller BM. 1999. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res 250:231-240.